We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
News

Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery

Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
News

Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cenix BioScience GmbH (Dresden) has announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latter’s efforts in the discovery and validation of novel therapeutic drug targets.

Cenix will apply its well-established expertise in combining high throughput (HT) applications of RNAi-based gene silencing, the technology behind the 2006 Nobel Prize for Medicine, with high content phenotypic analyses in cultured human cells.

The initial project will involve a HT-RNAi screen using an assay strategy co-designed with AstraZeneca scientists to discover and validate novel oncology targets. Cenix will adapt and implement multi-parametric microscopy-based assays using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes. Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.

“We are very excited to begin working with AstraZeneca scientists to help advance their discovery pipeline with this powerful and well-proven technology,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.

“We look forward to driving this relationship beyond the initial pilot through to multiple projects, as we have successfully done with other major pharma partners: by exceeding expectations on scientific and strategic excellence, and delivering the most detailed and professional reporting available in this field,” Dr. Echeverri added.

Advertisement